Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-EN | Version v2-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2022-03-03 | 2022-02-24 |
| Drug Identification Number | 02483092 | 02483092 |
| Brand name | SUBLOCADE | SUBLOCADE |
| Common or Proper name | SUBLOCADE® (buprenorphine extended-release injection) 300 mg / 1.5 mL | SUBLOCADE® (buprenorphine extended-release injection) 300 mg / 1.5 mL |
| Company Name | INDIVIOR UK LIMITED | INDIVIOR UK LIMITED |
| Ingredients | BUPRENORPHINE | BUPRENORPHINE |
| Strength(s) | 300MG | 300MG |
| Dosage form(s) | SOLUTION (EXTENDED RELEASE) | SOLUTION (EXTENDED RELEASE) |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | 1 syringe/pack | 1 syringe/pack |
| ATC code | N07BC | N07BC |
| ATC description | ||
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2022-03-01 | 2022-03-01 |
| Actual start date | 2022-03-01 | |
| Estimated end date | 2022-03-05 | 2022-03-05 |
| Actual end date | 2022-03-02 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | There is an anticipated short-term backorder of SUBLOCADE® 300 mg supply, that may impact some pharmacies in Canada, for a few days during the first week of March. The anticipated shortage is caused by transportation challenges in North America and will impact the 300 mg dosage strength only. | There is an anticipated short-term backorder of SUBLOCADE® 300 mg supply, that may impact some pharmacies in Canada, for a few days during the first week of March. The anticipated shortage is caused by transportation challenges in North America and will impact the 300 mg dosage strength only. |
| Health Canada comments |